サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1588974

ワクチン受託製造の世界市場

Vaccine Contract Manufacturing

出版日
ページ情報
英文 274 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ワクチン受託製造の世界市場
出版日: 2024年11月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 274 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ワクチン受託製造の世界市場は2030年までに70億米ドルに到達

2023年に42億米ドルと推定されるワクチン受託製造の世界市場は、分析期間2023-2030年にCAGR 7.5%で成長し、2030年には70億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである弱毒化ワクチンは、CAGR 7.3%を記録し、分析期間終了時には26億米ドルに達すると予測されます。不活化ワクチン分野の成長率は、分析期間中CAGR 7.0%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 11.5％で成長予測

米国のワクチン受託製造市場は2023年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに18億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは11.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3%と6.6%と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界のワクチン受託製造市場- 主要動向と促進要因まとめ

ワクチン受託製造とは何か、なぜ現代ヘルスケアにおいて重要なのか？

ワクチン受託製造では、ワクチン製造を専門の開発・製造受託機関（CDMO）に委託しています。これらのCDMOは、プロセス開発、スケールアップ、大量生産、製剤化、充填仕上げ、包装、品質管理など、エンド・ツー・エンドのサービスを提供します。ワクチン・メーカーはCDMOと提携し、CDMOの専門知識、技術、設備を活用することで、より迅速でコスト効率の高い製造を可能にしています。このアプローチは、生産能力の拡大を目指す大手製薬会社や、独自のインフラを構築せずにワクチン開発を加速する必要のあるバイオテクノロジー新興企業にとって特に有益です。

ワクチン受託製造の重要性は、生産を迅速に拡大し、柔軟性を高め、特にパンデミックや疾病の発生時など需要が高い時に、ワクチンへの世界のアクセスを確保する能力にあります。大規模生産を可能にすることで、CDMOはワクチンがより迅速かつ低コストで市場に届くよう支援し、世界中の公衆衛生イニシアチブをサポートします。COVID-19パンデミックは、CDMOが製薬会社の迅速な承認と大規模なワクチン流通を支援することで、前例のない世界的需要に対応する上で製造委託が果たす重要な役割を浮き彫りにしました。ワクチンのパイプラインが感染症、がん、新興病原体などのワクチンを含め、拡大・多様化し続ける中、効率的で信頼性が高く、スケーラブルなワクチン製造をサポートする上で、受託製造は不可欠なものとなっています。

技術の進歩はどのようにワクチン受託製造市場を形成しているか？

技術の進歩により、ワクチン受託製造の効率性、拡張性、品質が大幅に改善され、ワクチン開発と生産におけるイノベーションが推進されています。この技術は、従来のステンレス製バイオリアクターに比べて、柔軟性、ターンアラウンドタイムの短縮、汚染リスクの低減を実現します。シングルユースシステムは、ウイルスベクターワクチン、mRNAワクチン、組換えタンパク質ワクチンの製造に特に有利で、CDMOは異なるタイプのワクチンを迅速かつコスト効率よく切り替えることができます。

mRNAワクチン製造の進歩も受託製造の形を変えており、CDMOは特殊なmRNA合成、カプセル化、脂質ナノ粒子（LNP）技術に多額の投資を行っています。これらの技術革新は、迅速なスケールアップと高い収率を可能にし、COVID-19だけでなく、インフルエンザ、RSV、がんなどの他の疾患に対するmRNAワクチンの開発を支えています。自動化とデジタル化はワクチン製造ラインを変革し、工程管理を改善し、人的ミスを減らし、リアルタイムのモニタリングを可能にしています。AIや機械学習ツールがワクチン製造のワークフローに組み込まれ、製造工程の最適化、バッチの一貫性の強化、品質管理の迅速化が図られています。

自動無菌充填システム、凍結乾燥、先進パッケージング・ソリューションにより、ワクチンの安定性、保存期間、流通が改善されています。これらの技術革新は、ワクチンが安全かつ効率的に製造・包装され、厳しい規制基準に適合することを保証します。CDMOはまた、中断のない製造とリアルタイムの品質保証を可能にする連続製造プロセスも取り入れており、効率の向上とコスト削減を実現しています。このような技術革新は、ワクチン製造の能力とスピードを向上させるだけでなく、より迅速で、適応性が高く、拡張性のある製造ソリューションに対する世界の需要にも合致しています。

様々なワクチンタイプにおけるワクチン受託製造の新たな応用例とは？

ワクチン受託製造は、特殊な製造能力に対する需要の高まりにより、様々なワクチンタイプで応用が広がっています。生ワクチン、不活化ワクチン、サブユニットワクチンのような伝統的なワクチンでは、CDMOは製造管理及び品質管理基準（GMP）に適合した大規模な製造施設を提供し、高品質で信頼性の高い生産物を保証しています。これらのワクチンは、ポリオ、肝炎、麻疹などの疾病を対象とする定期予防接種プログラムにとって、依然として不可欠なものです。契約製造業者は、特に公衆衛生にとってワクチンへのアクセスが不可欠な中低所得国において、世界の予防接種のニーズを満たすために製造規模を拡大する上で重要な役割を果たしています。

mRNAワクチン、DNAワクチン、ウイルスベクターワクチンのような次世代ワクチンの製造は、製造受託の重要な焦点となっています。CDMOは、mRNA合成、ベクター製造、ウイルスカプセル化などの機能を提供し、これらの革新的なプラットフォームをサポートするために急速に適応してきました。例えば、COVID-19パンデミックの際に迅速な開発と拡張性を示したmRNAワクチンは、CDMOが独自に対応できる特殊な製造工程を必要とします。また、小ロットで患者ごとに製造する個別化がんワクチンに注目が集まっていることも、小規模で精密な製造に対応できる柔軟な製造体制を持つCDMOへの需要を高めています。

感染症ワクチンに加え、受託製造はがん、自己免疫疾患、アレルギーをターゲットとした治療用ワクチンにも拡大しています。これらのワクチンは、細胞ベースのプラットフォーム、組換えタンパク質、新規アジュバント製剤など、複雑な製造方法を必要とすることが多いです。CDMOは、バイオテクノロジー企業と協力してこれらの治療用ワクチンを開発・製造し、効率的な製造と規制基準の遵守を実現しています。これらのワクチンタイプにおいて製造受託の用途が拡大していることは、多様な製造ニーズに対応し、開発期間を短縮し、救命ワクチンへの幅広いアクセスを可能にするという重要な役割を反映しています。

ワクチン受託製造市場の成長の原動力は？

ワクチン受託製造市場の成長は、ワクチン需要の増加、ワクチンパイプラインの拡大、スケーラブルな生産ソリューションの必要性など、いくつかの要因によってもたらされます。主な成長要因の1つは、新興感染症、季節的流行（例：インフルエンザ）、集団予防接種キャンペーンの必要性に後押しされたワクチンに対する世界の需要の高まりです。COVID-19パンデミックは、スケーラブルで迅速なワクチン製造の緊急性を浮き彫りにし、世界のワクチン接種目標の達成に製造委託が重要な役割を果たすことを実証しました。製薬会社や政府がパンデミックへの備えやワクチンの備蓄に投資する中、CDMOへのサージ能力への依存が高まり、市場の成長を牽引しています。

感染症や治療用途のmRNA、DNA、ウイルスベクター、タンパク質ベースのワクチン開発など、ワクチンパイプラインの多様化も製造受託の需要を促進しています。バイオテクノロジー企業や新興企業、学術機関には、商業規模でワクチンを製造するインフラがないことが多く、CDMOはこうした革新的なワクチンを市場に投入する上で不可欠なパートナーとなっています。COVID-19以外にも、インフルエンザ、RSV、ジカウイルス、個別化がんワクチンなどをターゲットとしたmRNAワクチンが急成長しており、mRNA合成、脂質ナノ粒子カプセル化、充填仕上げサービスなどの専門的な受託製造能力に対するニーズがさらに高まっています。

特に中低所得国におけるワクチン製造能力の拡大を目指した規制支援や政府の取り組みも、市場成長に寄与しています。各国政府は、現地での製造能力を確保し、ワクチンへのアクセスを改善するため、インフラ、パートナーシップ、CDMOとの技術移転契約に投資しています。供給の途絶を緩和し、ワクチンの公平性を向上させる必要性から、より弾力的な世界・サプライチェーンを推進する動きが、製造受託への需要をさらに加速させています。ワクチン技術、製造方法、デジタル化の革新が進む中、ワクチン受託製造市場は、公衆衛生、パンデミックへの備え、ワクチン入手のしやすさを改善するための世界の取り組みに支えられ、力強い成長を遂げようとしています。

調査対象企業の例（注目の34社）

  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Catalent, Inc.
  • Cobra Bio
  • Cytovance Biologics
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Icon plc
  • IDT Biologika
  • KBI Biopharma
  • Lonza

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP23009

Global Vaccine Contract Manufacturing Market to Reach US$7.0 Billion by 2030

The global market for Vaccine Contract Manufacturing estimated at US$4.2 Billion in the year 2023, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Attenuated Vaccine, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Inactivated Vaccine segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 11.5% CAGR

The Vaccine Contract Manufacturing market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Vaccine Contract Manufacturing Market - Key Trends & Drivers Summarized

What Is Vaccine Contract Manufacturing, and Why Is It So Crucial in Modern Healthcare?

Vaccine Contract Manufacturing involves outsourcing vaccine production to specialized contract development and manufacturing organizations (CDMOs). These CDMOs provide end-to-end services, including process development, scale-up, bulk production, formulation, fill-finish, packaging, and quality control. Vaccine manufacturers partner with CDMOs to leverage their expertise, technology, and facilities, allowing for faster, more cost-effective production. This approach is particularly beneficial for large pharmaceutical companies looking to expand capacity and for biotech startups that need to accelerate vaccine development without building their own infrastructure.

The importance of vaccine contract manufacturing lies in its ability to rapidly scale up production, enhance flexibility, and ensure global access to vaccines, particularly in times of high demand, such as during pandemics or disease outbreaks. By enabling large-scale production, CDMOs help ensure that vaccines reach markets more quickly and at a lower cost, supporting public health initiatives worldwide. The COVID-19 pandemic underscored the critical role of contract manufacturing in meeting unprecedented global demand, with CDMOs helping pharmaceutical companies achieve faster approvals and large-scale vaccine distribution. As vaccine pipelines continue to expand and diversify—including vaccines for infectious diseases, cancer, and emerging pathogens—contract manufacturing has become indispensable in supporting efficient, reliable, and scalable vaccine production.

How Are Technological Advancements Shaping the Vaccine Contract Manufacturing Market?

Technological advancements have significantly improved the efficiency, scalability, and quality of Vaccine Contract Manufacturing, driving innovation in vaccine development and production. One of the major developments is the adoption of single-use bioreactor technology, which offers flexibility, faster turnaround times, and reduced contamination risks compared to traditional stainless-steel bioreactors. Single-use systems are particularly advantageous for producing viral vector vaccines, mRNA vaccines, and recombinant protein vaccines, allowing CDMOs to switch between different vaccine types quickly and cost-effectively.

Advancements in mRNA vaccine production have also reshaped contract manufacturing, with CDMOs investing heavily in specialized mRNA synthesis, encapsulation, and lipid nanoparticle (LNP) technologies. These innovations allow for rapid scale-up and higher yields, supporting the development of mRNA vaccines not only for COVID-19 but also for other diseases like influenza, RSV, and cancer. Automation and digitalization are transforming vaccine production lines, improving process control, reducing human error, and enabling real-time monitoring. AI and machine learning tools are being integrated into vaccine manufacturing workflows to optimize production processes, enhance batch consistency, and accelerate quality control.

Another key advancement is in fill-finish technology, where automated aseptic filling systems, lyophilization (freeze-drying), and advanced packaging solutions have improved vaccine stability, shelf life, and distribution. These innovations ensure that vaccines are produced and packaged safely and efficiently, meeting stringent regulatory standards. CDMOs are also incorporating continuous manufacturing processes, which enable uninterrupted production and real-time quality assurance, improving efficiency and reducing costs. These technological innovations not only enhance the capacity and speed of vaccine production but also align with global demands for faster, more adaptable, and scalable manufacturing solutions.

What Are the Emerging Applications of Vaccine Contract Manufacturing Across Different Vaccine Types?

Vaccine Contract Manufacturing is finding expanding applications across a diverse range of vaccine types, driven by increasing demand for specialized production capabilities. For traditional vaccines like live-attenuated, inactivated, and subunit vaccines, CDMOs provide large-scale production facilities that meet Good Manufacturing Practice (GMP) standards, ensuring high-quality and reliable output. These vaccines remain critical for routine immunization programs, targeting diseases like polio, hepatitis, and measles. Contract manufacturers play a crucial role in scaling up production to meet global immunization needs, particularly in low- and middle-income countries where vaccine access is vital for public health.

The production of next-generation vaccines, such as mRNA vaccines, DNA vaccines, and viral vector vaccines, has become a significant focus for contract manufacturing. CDMOs have rapidly adapted to support these innovative platforms, providing capabilities for mRNA synthesis, vector production, and viral encapsulation. For example, mRNA vaccines, which demonstrated rapid development and scalability during the COVID-19 pandemic, require specialized manufacturing processes that CDMOs are uniquely equipped to handle. The increasing focus on personalized cancer vaccines, which involve small-batch, patient-specific production, is also driving demand for CDMOs with flexible manufacturing setups that can accommodate small-scale, precision-focused production.

In addition to infectious disease vaccines, contract manufacturing is expanding into therapeutic vaccines targeting cancer, autoimmune diseases, and allergies. These vaccines often require complex production methods, including cell-based platforms, recombinant proteins, and novel adjuvant formulations. CDMOs are collaborating with biotech companies to develop and manufacture these therapeutic vaccines, ensuring efficient production and adherence to regulatory standards. The expanding applications of contract manufacturing across these vaccine types reflect its critical role in meeting diverse production needs, accelerating development timelines, and enabling broader access to life-saving vaccines.

What Drives Growth in the Vaccine Contract Manufacturing Market?

The growth in the Vaccine Contract Manufacturing market is driven by several factors, including the increasing demand for vaccines, the expansion of vaccine pipelines, and the need for scalable production solutions. One of the primary growth drivers is the rising global demand for vaccines, fueled by emerging infectious diseases, seasonal epidemics (e.g., influenza), and the need for mass immunization campaigns. The COVID-19 pandemic highlighted the urgency of scalable, rapid vaccine production, demonstrating the vital role of contract manufacturing in achieving global vaccination goals. As pharmaceutical companies and governments invest in pandemic preparedness and vaccine stockpiling, the reliance on CDMOs for surge capacity has increased, driving market growth.

The diversification of vaccine pipelines, with the development of mRNA, DNA, viral vector, and protein-based vaccines for both infectious diseases and therapeutic applications, has also fueled the demand for contract manufacturing. Biotech companies, startups, and academic institutions often lack the infrastructure to produce vaccines at commercial scale, making CDMOs essential partners in bringing these innovative vaccines to market. The rapid growth of mRNA vaccines beyond COVID-19—targeting conditions like influenza, RSV, Zika virus, and personalized cancer vaccines—has further driven the need for specialized contract manufacturing capabilities, including mRNA synthesis, lipid nanoparticle encapsulation, and fill-finish services.

Regulatory support and government initiatives aimed at expanding vaccine manufacturing capacity, particularly in low- and middle-income countries, have also contributed to market growth. Governments are investing in infrastructure, partnerships, and technology transfer agreements with CDMOs to ensure local production capacity and improve access to vaccines. The push for more resilient global supply chains, driven by the need to mitigate supply disruptions and improve vaccine equity, has further accelerated demand for contract manufacturing. With ongoing innovations in vaccine technologies, production methods, and digitalization, the Vaccine Contract Manufacturing market is poised for robust growth, supported by global efforts to improve public health, pandemic preparedness, and vaccine accessibility.

Select Competitors (Total 34 Featured) -

  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Catalent, Inc.
  • Cobra Bio
  • Cytovance Biologics
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Icon plc
  • IDT Biologika
  • KBI Biopharma
  • Lonza

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Vaccine Contract Manufacturing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Vaccines Drives Adoption of Contract Manufacturing Services
    • Expanding Role of CMOs (Contract Manufacturing Organizations) Propels Vaccine Manufacturing
    • Focus on Cost-Effective Vaccine Manufacturing Boosts CMO Market
    • Growing Role of Outsourcing in Vaccine Production Sets the Stage for CMO Growth
    • Regulatory Push for Faster Vaccine Approvals Drives CMO Market Expansion
    • Increasing Investments in Biologics Propel Vaccine Contract Manufacturing
    • Demand for mRNA Vaccine Production Enhances Contract Manufacturing Opportunities
    • Case Overview: Demand for Fill-and-Finish Services Boosts Vaccine CMO Adoption
    • Growing Use of Single-Use Bioprocessing in Vaccine Manufacturing Bodes Well for CMOs
    • Demand for High-Quality Vaccine Production Sets the Stage for CMO Market
    • Push for Pandemic Preparedness Drives Vaccine Contract Manufacturing
    • Expansion of Vaccines for Emerging Diseases Boosts CMO Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Subunit-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Toxoid-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for DNA-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Veterinary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Vaccine Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • JAPAN
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • CHINA
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • EUROPE
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • FRANCE
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • GERMANY
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • INDIA
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Vaccine Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Vaccine Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
  • AFRICA
    • Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030

IV. COMPETITION